February 20, 2024
Apollon Formularies
Plc
("Apollon" or the
"Company")
APOLLON FORMULARIES
SUCCESSFUL CANCER CELL KILLING RESULTS PUBLISHED IN THE
PEER-REVIEWED ONLINE JOURNAL OF COMPLEMENTARY AND ALTERNATIVE
MEDICINE (OJCAM)
London, England - Apollon Formularies PLC
(AQUS:APOL), an innovator in medical cancer research, proudly
announces the peer-reviewed publication of their groundbreaking
achievement in pre-clinical testing of Apollon's cancer therapeutic
formulations.
Utilising a strategic
combination of medical cannabis and medicinal mushroom compounds,
Apollon demonstrated successful cancer cell-killing results in
prostate cancer, breast cancer, colon cancer, lung cancer, bladder
cancer, and skin cancer through direct cytotoxicity and
immune-targeted eradication of the cancer cells by T-cells and
macrophages in blinded studies, performed by Bioensis Labs, as an
independent third party testing
facility.
The pioneering research,
enriched by advanced AI-derived drug discovery techniques, has
undergone rigorous peer review and has been formally published in
the Online Journal of Complementary and Alternative Medicine
(OJCAM).
Key Highlights of the
Pre-Clinical Study:
-
AI-Derived Drug
Discovery: Apollon Formularies PLC
employs advanced AI techniques in drug discovery, leading to
successful outcomes in killing cells from multiple cancer
types.
-
Successful Pre-Clinical
Cancer Cell Killing Results: The pre-clinical study
demonstrated remarkable success in eradicating cancer cells in
blinded studies, performed by Bioensis Labs, as an independent
third party testing facility, with promising outcomes in prostate
cancer, breast cancer, colon cancer, lung cancer, bladder cancer,
and skin cancer
-
Published in Peer-Reviewed
Journal: The results have been
peer-reviewed and officially published in the Online Journal of
Complementary and Alternative Medicine (OJCAM), contributing to the
scientific community's understanding of innovative natural cancer
treatments.
The pre-clinical study,
spearheaded by Dr. Herbert Fritsche,
former Professor and Chief of Clinical Chemistry at MD Anderson
Cancer Center and Chief Science Officer of Apollon, delved into the
synergistic potential of medical cannabis and medicinal mushrooms.
The results showcase unprecedented efficacy in eradicating cancer
cells, suggesting potential for use in the treatment of cancers of
the prostate, breast, colon, lung, bladder, and skin. The
cytotoxicity of our formulations was established in blinded
studies, performed by Bioensis Labs, as an independent third
party.
Dr. Herbert Fritsche, Principal Investigator of the
study, highlighted the scientific significance of the research,
saying, "The successful cell-killing activity of our formulations
in these various pre-clinical models, as published in the
peer-reviewed Online Journal of Complementary and Alternative
Medicine, demonstrate the potential of these formulations for
developing innovative, low cost, non-toxic and highly effective
cancer treatments."
Dr. Stephen Barnhill, a medical doctor and CEO of
Apollon Formularies PLC, expressed his excitement about the
transformative findings, stating, "This pre-clinical success is a
significant leap forward in our mission to redefine cancer
treatment. The promising outcomes across various cancer types,
underscore Apollon's dedication to advancing patient-centric
healthcare. We believe that our proprietary formulations, guided by
AI-derived drug discovery techniques, hold great promise for the
future of cancer therapies."
This pre-clinical research
marks a significant step forward in the development of effective
and targeted natural cancer therapies. The complete pre-clinical
study can be accessed in the peer-reviewed Online Journal of
Complementary and Alternative Medicine (OJCAM) https://irispublishers.com/ojcam/pdf/OJCAM.MS.ID.000700.pdf.
Jeff Nagel, Director of Product Manufacturing at
Apollon Formularies PLC, underscored the practical implications of
the results, stating, "Our proprietary formulations have now
demonstrated success in targeting malignant cells across
numerous cancer types in pre-clinical testing. As we move forward,
we are dedicated to translating these promising findings into
tangible solutions for patients in need
globally."
Apollon Formularies is
enthusiastic about cultivating collaborative partnerships that
epitomize adaptability and innovation. With a global outlook and a
versatile array of capabilities, our company is poised to engage
with potential strategic partners. Whether exploring in-and-out
licensing agreements, engaging in collaborative research and
development initiatives, forming international joint ventures,
establishing strategic alliances, exploring import/export
opportunities, or leveraging our academic affiliation and clinical
trial capabilities, Apollon is resolute in its dedication to
closely collaborating with like-minded partners. Together, we aim
to unite efforts and bring state-of-the-art medicine to patients on
a global scale.
For media inquiries or to
initiate discussions about potential partnerships, please reach out
to Stene Jacobs, Global COO for
Apollon at stene@Apollon.org.uk.
The directors of the
Company accept responsibility for the contents of this
announcement.
For additional
information, please visit www.apollon.org.uk or
contact:
Apollon
Formularies
Tel:
+44 771 198 0221
Stene
Jacobs stene@apollon.org.uk
Peterhouse Capital
Limited (Corporate Adviser)
Tel:
+44 207 220 9795
Guy
Miller
gm@peterhousecapital.com
About Apollon and Apollon
Jamaica
Apollon Formularies
plc is an international medical cannabis and medicinal
mushroom pharmaceutical company headquartered in the United
Kingdom. Apollon Formularies Jamaica Limited is a
pharmaceutical company incorporated and operating in the
Commonwealth of Jamaica since 2016. Apollon Jamaica is licensed by the Jamaican
government's Cannabis Licensing Authority (CLA) to
cultivate (R&D), perform research and development, process, and
sell medical cannabis therapeutic products that include legal
medical cannabis to treat various illnesses under medical
supervision.